Century Therapeutics, Inc. (NASDAQ:IPSC – Get Free Report) has been given an average recommendation of “Buy” by the five ratings firms that are currently covering the firm, Marketbeat.com reports. Five research analysts have rated the stock with a buy rating. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $6.50.
A number of equities analysts have issued reports on the stock. Piper Sandler decreased their price objective on shares of Century Therapeutics from $12.00 to $4.00 and set an “overweight” rating on the stock in a research report on Monday, December 30th. Guggenheim restated a “buy” rating on shares of Century Therapeutics in a research report on Wednesday, January 22nd. Finally, HC Wainwright restated a “buy” rating and issued a $5.00 price objective on shares of Century Therapeutics in a research report on Wednesday, January 22nd.
Get Our Latest Research Report on IPSC
Institutional Inflows and Outflows
Century Therapeutics Stock Performance
IPSC stock opened at $0.63 on Thursday. Century Therapeutics has a 52 week low of $0.55 and a 52 week high of $5.24. The firm’s fifty day moving average is $0.78 and its 200 day moving average is $1.19. The firm has a market cap of $53.17 million, a P/E ratio of -0.34 and a beta of 1.75.
Century Therapeutics Company Profile
Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.
Recommended Stories
- Five stocks we like better than Century Therapeutics
- Insider Trading – What You Need to Know
- Can TikTok Stock Picks Really Make You Rich?
- Insider Buying Explained: What Investors Need to Know
- The “Quality” Rotation: Back to Basics Investing
- Trading Halts Explained
- Occidental Petroleum: 4 Reasons to Love These Prices
Receive News & Ratings for Century Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Century Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.